DOI: https://doi.org/10.24026/1818-1384.2(35).2011.86257

Фармакоепідеміологічна та фармакоекономічна оцінка лікування хворих на цукровий діабет

Л. В. Яковлева, О. Н. Кириченко

Анотація


The review deals the results of comparative studies of pharmacoeconomic efficacy of drugs for insulin replacement therapy – genetically engineered prolonged human insulin and analogs of human insulin of nonpeak action (glargine, detemir). Evidence of high economic effectiveness of insulin glargine is shown. The need to conduct clinical and economic studies of insulin glargine in Ukraine and the establishment of national economic criteria for eligibility of additional costs are indicated.

Ключові слова


insulin analogues; glargine; pharmacoeconomic effectiveness; diabetes mellitus; insulin therapy

Повний текст:

PDF

Посилання


http://www.who.int/diabetes/facts/en.

http://www.diabetesatlas.org/sites/default/files/IDF%20Diabetes%20Atlas2007%20(3rd%20edition).pdf.

Аметов А. С., Демидова Т. Ю., Ерохина Е. Н. Роль и место Авандии в профилактике сахарного диабета 2 типа [Электронный ресурс] // http://www.rmj.ru/articles/endokrinologiya/Roly_i_mesto_Avandii_v_profilaktike_saharnogo_diabeta_2_tipa/

Верткин А. Л., Аристархова О. Ю., Скотникова А. С. Роль современных сахароснижающих и антиоксидантных препаратов в фармакотерапии сахарного диабета 2-го типа и его осложнений [Электронный ресурс] // Лечащий врач. http://www.vrach.ru.

Демидова Т. Ю. Сосудистые осложнения сахарного диабета 2 типа за гранью гликемического контроля / Т. Ю. Демидова // Сахарный диабет. – 2010. – № 3(48). – С. 111-116.

Мамедов М. Н. Диагностика, профилактика и лечение сахарного диабета и его осложнений (по материалам 19 всемирного когресса Международной федерации диабета) / М. Н. Мамедов. // Кейптаун, ЮАР, 2006. – 46 с.

Дедов И. И. Сахарный диабет: развитие технологий в диагностике, лечении и профилактике (пленарная лекция) / И. И. Дедов // Сахарный диабет. – 2010. – № 3(48). – С. 6-13.

Hogan P., Dall T., Nikolov P. Economic costs of diabetes in the US in 2002 // Diabetes Care. – 2003. – Vol. 26. – P. 917-932. https://doi.org/10.2337/diacare.26.3.917

Economic costs of diabetes in the US in 2007 // Diabetes Care. – 2008. – Vol. 31(3). – P. 596-615. https://doi.org/10.2337/dc08-9017

Clarke P., Gray A., Legood R., Briggs A., Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No 65) // Diabetic Medicine. – 2003. – Vol. 20. – P. 442-450. https://doi.org/10.1046/j.1464-5491.2003.00972.x

Крысанов И. С. Фармакоэкономика сахарного диабета / И. С. Крысанов // Фармакоэкономика. – 2009. – № 1. – С. 42-47.

http://www.diabetesatlas.org.

Общее руководство по лечению диабета 2 типа. Брюссель: Международная диабетическая федерация, 2005. Москва. 2007. – С. 80. [Электронный ресурс] // www.idf.ors.

UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. – 1998. – Vol. 352. – P. 837-853. https://doi.org/10.1016/s0140-6736(98)07019-6

Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C.E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., de Galan B.E., Joshi R., Travert F. ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. – 2008. – Vol. 358. – P. 2560-2572. https://doi.org/10.1056/nejmoa0802987

Gerstein H.C., Miller M.E., Byington R.P., Golf D.C. Jr, Bigger J.T., Buse J.B., Cushman W.C., Genuth S., Ismail-Beigi F., Grimm R.H. Jr, Probstfield J.L., Simons-Morton D.G., Friedwald W.T. Action to Control Cardiovascualr Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. – 2008. – Vol. 358. – P. 2545-2559. https://doi.org/10.1056/nejmoa0802743

Duckworth W., Abraira C., Moritz T., Reda D., Emannele N., Reaven P.D., Zieve F.J., Marks J., Davis S.N., Hayward R., Warren S.R., Goldman S., McCarren M., Vikek M.E., Henderson W.G., Huang G.D. VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes // N. Engl. J. Med. – 2009. – Vol. 360(2). – P. 129-139. https://doi.org/10.1056/nejmoa0808431

Stettler C., Allemann S., Juni P., Cull C.A., Holman R.R., Egger M. et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials // Am. Heart J. – 2006. – Vol. 152(1). – P. 27-38. https://doi.org/10.1016/j.ahj.2005.09.015

Stratton I.M., Adler A.I., Neil A.W., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R. UK Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study // BMJ. – 2000. – Vol. 321. – P. 405-412. https://doi.org/10.1136/bmj.321.7258.405

Мкртумян А. М. Уровень гликемии как фактор риска сердечно-сосудистых заболеваний / А. М. Мкртумян // Сахарный диабет. – 2010. – № 3 (48). – С. 80-82.

Bjork S. The cost of diabetes and diabetes care / / Diabetes Research and Clinical Practice. – 2001. – Vol. 54(1). – P. S13-S18. https://doi.org/10.1016/s0168-8227(01)00304-7

Edward H.W. et al. Effect of Improved Glycemic Control on Health Care Costs and Utilization // JAMA. – 2001. – Vol. 285. – P. 182-189. https://doi.org/10.1001/jama.285.2.182

Дедов И. И., Шестакова М. В., Моисеев С. В. Аналогия инсулина // Клиническая фармакология и терапия. – 2005. – № 14 (2). [Электронный ресурс] http://www.voed.ru.

McIntosh A., Hutchinson A., Home P.D., Brown F., Bruce A., Damerell A. et al. Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose. Sheffield: ScHARR, University of Sheffield, 2001. http://www.nice.org.uk/pdf/NICE_full_blood_glucose.pdf

Вербовая Н. И. Аналоги инсулина пролонгированного действия: сравнительная характеристика строения, фармакологических свойств, возможностей клинического применения / Проф., зав. каф. Н. И. Вербовая // Проблемы эндокринологии. – 2010. – № 2. – С.64-71. https://doi.org/10.14341/probl201056264-71

Heinemann L., Linkeschova R., Rave K. et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo // Diabetes Care. – 2000. – Vol. 23. – P. 644-649. https://doi.org/10.2337/diacare.23.5.644

Fanelli G.C., Pampanelli S., Porcellati F. et al. Administration of neutral protamine Hagedorn insulin at bedtime versus dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial // Ann. Intern. Med. – 2002. – Vol. 136. – P. 504-514. https://doi.org/10.7326/0003-4819-136-7-200204020-00007

Hirsch I. Insulin analogues // N. Engl. J. Med. – 2005. – Vol. 352. – P. 174-183. https://doi.org/10.1056/nejmra040832

Lepore M., Pampanelli S., Fanelli C. et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro // Diabetes. – 2000. – Vol. 49. – P. 2142-2148. https://doi.org/10.2337/diabetes.49.12.2142

Heise T., Nosek L., Ronn B.B. et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes // Diabetes. – 2004. – Vol. 53(6). – P. 1614-1620. https://doi.org/10.2337/diabetes.53.6.1614

Porcellati F., Rossetti P., Busciantella Ricci N. et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after one week of use as compared to its first administration in subjects with Type 1 diabetes mellitus // Diabetes Care. – 2007. – Vol. 30. – P. 1261-1263. https://doi.org/10.2337/dc06-2208

Кураева Т. Л. Аналоги инсулина в достижении компенсации и улучшения качества жизни детей и подростков с сахарным диабетом 1 типа / Т. Л. Кураева // Сахарный диабет. – 2010. – № 3(48). – С. 147-152.

Plank J., Bodenlenz M., Sinner F. et al. A doubleblind, randomized, dose response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir // Diabetes Care. – 2005. – Vol. 28. – P. 1107-1112. https://doi.org/10.2337/diacare.28.5.1107

Wutte A., Plank J., Bodenlenz M. et al. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus// Exp. Clin. Endocrinol. Diabetes. – 2007. – Vol. 115. – P. 461-467. https://doi.org/10.1055/s-2007-976512

Klein O., Lynge J., Endahl L. et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes // Diabetes Obes. Metab. – 2007. – Vol. 9. – P. 290-299. https://doi.org/10.1111/j.1463-1326.2006.00685.x

Peter R., Luzio S.D., Dunseath G. et al. Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes // Diabetes Care. – 2005. – Vol. 28. – P. 560-565. https://doi.org/10.2337/diacare.28.3.560

Eliaschewitz F.G., Calvo C., Valbuena H. et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride // Arch. Med. Res. – 2006. – Vol. 37. – P. 495-501. https://doi.org/10.1016/j.arcmed.2005.10.015

Rosenstock J., Schwartz S.L., Clark C.M. Jr. et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin // Diabetes Care. – 2001. – Vol. 24. – P. 631-636. https://doi.org/10.2337/diacare.24.4.631

Porcellati F., Rossetti P., Busciantella S. et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, crossover study // Diabetes Care. – 2007. – Vol. 30. – P. 2447-2452. https://doi.org/10.2337/dc07-0002

Meneghini L.F., Rosenberg K.H., Koenen C. et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: Clinical practice experience from a German subgroup of the PREDICTIVE study // Diabetes Obes. Metab. – 2007. – Vol. 9. – P. 418-427. https://doi.org/10.1111/j.1463-1326.2006.00674.x

Fritsche A., Haring H. At last, a weight-neutral insulin? // Int. J. Obes. – 2004. – Vol. 28(2). – P. S41-S46. https://doi.org/10.1038/sj.ijo.0802749

Hompesch M., Troupin B., Heise T. et al. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from diferent ethnic groups // Diabetes Obes. Metab. – 2006. – Vol. 8. – P. 568-573. https://doi.org/10.1111/j.1463-1326.2006.00643.x

Rosenstock J., Dailey G., Massi-Benedetti M., et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes // Diabetes Care. – 2005. – Vol. 28(4). – P. 950-955. https://doi.org/10.2337/diacare.28.4.950

Белоусов Д. Ю. Фармаэкономика инсулина гларгина (Лантус) в зеркале зарубежных доказательных исследований: обзор литературы / Д. Ю. Белоусов // Клиническая фармакология и терапия. – 2008. – №17(2). – C. 1-18.

Riddle M.C., Rosenstock J., Gerich J. et al. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients // Diabetes Care. – 2003. – Vol. 26(11). – P. 3080-3086. https://doi.org/10.2337/diacare.26.11.3080

HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients // Diabet. Med. – 2003. – Vol. 20(7). – P. 545-551. https://doi.org/10.1046/j.1464-5491.2003.00999.x

Ацинферов М. Б., Петранева Е. В. Возможности применения инсулина гларгин (Лантус®) для лечения сахарного диабета типа 2 в работе эндокринологической службы: результаты анализа регистра LAUREL / М. Б. Ацинферов, Е. В. Петранева // Фарматека. – 2009. – № 3. – С. 65-69.

Ацинферов М. Б. Применение аналогов инсулина пролонгированного действия в лечение сахарного диабета типа 2 (по данным международных и росийских регистров) / М. Б. Ацинферов // Фарматека. – 2010. – № 3. – С. 16-21.

Witthaus E., Stewart J., Bradley C .Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes // Diabet. Med. – 2001. – Vol. 18(8). – P. 619-625. https://doi.org/10.1046/j.1464-5491.2001.00529.x

Diana I. Brixner, Carrie McAdam-Marx. Cost-Effectiveness of Insulin Analogs // The American journal of managed care. – 2008. – Vol. 14(11). – P. 766-775.

Valentine W.J., Palmer A.J., Erny-Albrecht K.M. et al. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH // Adv. Ther. – 2006. – Vol. 23(2). – P. 191-207. https://doi.org/10.1007/bf02850126

Grima D.T., Thompson M.F., Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada // Pharmacoeconomics. – 2007. – Vol. 25(3). – P. 253-266. https://doi.org/10.2165/00019053-200725030-00007

McEwan P., Poole C.D., Tetlow T., Holmes P., Currie C.J. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK // Curr. Med. Res. Opin. – 2007. – Vol. 23(1). – P. 7-19. https://doi.org/10.1185/030079906x167561

Palmer A.J., Roze S., Valentine W.J., Smith I., Wittrup-Jensen K.U. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials // Curr. Med. Res. Opin. – 2004. – Vol. 20(11). – P. 1729-1746. https://doi.org/10.1185/030079904x5661

Palmer A.J., Roze S., Valentine W.J., et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making // Curr. Med. Res. Opin. – 2004. – Vol. 20(1). – P. S5-S26. https://doi.org/10.1185/030079904x1980

Bullano M.F., Al-Zakwani I.S., Fisher M.D., Menditto L., Willey V.J. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products // Curr. Med. Res. Opin. – 2005. – Vol. 21(2). – P. 291-298. https://doi.org/10.1185/030079905x26234

Miller D.M., Gardner J., Hendricks A., Fincke G., Zhang Q. Changes in health care utilization and expenditures associated with insulin glargine use [abstract] // Diabetes. – 2005. – Vol. 54(1). – P. A302.

Levin P. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics // Diabetes Obes. Metab. – 2008. – Vol. 10(2). – P. 66-75. https://doi.org/10.1111/j.1463-1326.2008.00845.x

Rosenstock J., Davies M., Home P. et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes // Diabetologia. – 2008. – Vol. 51(3). – P. 408-416. https://doi.org/10.1007/s00125-007-0911-x

Колбин А. С. Оптимизация базально-болюсной инсулинотерапии сахарного диабета 2 типа на основе фармакоэкономического анализа // Клиническая фармакология и терапия. – 2008. – № 17 (5). – C. 92-96.

Шестакова М. В., Халимов Ю. Ш., Новиков В. И. и др. Клинико-экономический анализ инсулина гларгин при сахарном диабете типа 2 // Клиническая фармакология и терапия. – 2009. – № 18 (2). – С. 1-5.

Brandle M., Azoulay M., Greiner R.A. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland // Int. J. Clin. Pharmacol. Ther. – 2007. – Vol. 45. – P. 203-220. https://doi.org/10.5414/cpp45203

Janka H.U., Hogy B. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial // Eur. J. Health Econ. – 2007. https://doi.org/10.1007/s10198-007-0057-2

Zhang Q., Menditto L. Incremental cost savings 6 months following initiation of insulin glargine in a Medicaid fee-for-service sample // Am. J. Ther. – 2005. – Vol. 12. – P. 337-343. https://doi.org/10.1097/01.mjt.0000160934.55260.d5

Miller D.R., Gardner J.A., Hendricks A.M., Zhang Q., Fincke B.G. Health care resource utilization and expenditures associated with the use of insulin glargine (to update) // Clin. Ther. – 2007. – Vol. 29. – P. 478-487. https://doi.org/10.1016/s0149-2918(07)80086-5


Пристатейна бібліографія ГОСТ








Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

© Clinical Endocrinology and Endocrine Surgery. Клінічна ендокринологія та ендокринна хірургія

ISSN: 1818-1384 (Print), e-ISSN: 2519-2582, DOI: 10.24026/1818-1384.

При копіюванні активне посилання на матеріал обов'язкове.

Flag Counter